



King's Research Portal

DOI: 10.1172/jci.insight.134310

Link to publication record in King's Research Portal

Citation for published version (APA):

Lodge, E. J., Xekouki, P., Silva, T. S., Kochi, C., Longui, C. A., Faucz, F. R., Santambrogio, A., Mills, J. L., Pankratz, N., Lane, J., Sosnowska, D., Hodgson, T., Patist, A. L., Francis-West, P., Helmbacher, F., Stratakis, C., & Andoniadou, C. L. (2020). Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development. *JCI Insight*, *5*(23), Article e134310. https://doi.org/10.1172/jci.insight.134310

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

JCI insight

Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development

Emily J. Lodge, ..., Constantine Stratakis, Cynthia L. Andoniadou

JCI Insight. 2020. https://doi.org/10.1172/jci.insight.134310.

Research In-Press Preview Development Endocrinology

Pituitary developmental defects lead to partial or complete hormone deficiency and significant health problems. The majority of cases are sporadic and of unknown cause. We screened 28 patients with pituitary stalk interruption syndrome (PSIS) for mutations in the FAT/DCHS family of protocadherins that have high functional redundancy. We identified seven variants, four of which putatively damaging, in *FAT2* and *DCHS2* in six patients with pituitary developmental defects recruited through a cohort of patients with mostly ectopic posterior pituitary gland and/or pituitary stalk interruption. All patients had growth hormone deficiency and two presented with multiple hormone deficiencies and small glands. FAT2 and DCHS2 were strongly expressed in the mesenchyme surrounding the normal developing human pituitary. We analyzed *Dchs2^{-/-}* mouse mutants and identified anterior pituitary morphogenesis defects were observed in *Fat4^{-/-}* and *Dchs1^{-/-}* mouse mutants but all animal models displayed normal commitment to the anterior pituitary cell type. Together our data implicate FAT/DCHS protocadherins in normal hypothalamic-pituitary development and identify *FAT2* and *DCHS2* as candidates underlying pituitary gland developmental defects such as ectopic pituitary gland and/or pituitary stalk interruption.



Find the latest version:

https://jci.me/134310/pdf

Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary

development

Emily J. Lodge^{1,*}, Paraskevi Xekouki^{1,2,*}, Tatiane S. Silva³, Cristiane Kochi³, Carlos A. Longui³,

Fabio R. Faucz⁴, Alice Santambrogio^{1,5}, James L. Mills⁶, Nathan Pankratz⁷, John Lane⁷,

Dominika Sosnowska¹, Tina Hodgson¹, Amanda L. Patist¹, Philippa Francis-West¹, Françoise

Helmbacher⁸, Constantine A. Stratakis⁴, Cynthia L. Andoniadou^{1,5}

¹Centre for Craniofacial and Regenerative Biology, King's College London, Floor 27 Tower Wing, Guy's Campus, London, SE1 9RT, United Kingdom

²Current address: Endocrinology and Diabetes Clinic, University General Hospital of Heraklion, University of Crete Medical School, Heraklion Crete, 71003, Greece

³Pediatric Endocrinology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil.

⁴Section on Endocrinology and Genetics, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, Maryland

⁵Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307, Germany

⁶Division of Intramural Population Health Research, Epidemiology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland, USA

⁷Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota, USA

⁸Aix Marseille Université, CNRS, IBDM - UMR7288, Marseille, France.

* These authors contributed equally to this work

Correspondence: Cynthia L. Andoniadou Address: Centre for Craniofacial and Regenerative Biology, King's College London, Floor 27 Tower Wing, Guy's Campus, London, SE1 9RT, United Kingdom Tel +44 207 188 7389 Fax +44 207 188 1674 Email : cynthia.andoniadou@kcl.ac.uk

The authors have declared that no conflict of interest exists.

1 Abstract

2 Pituitary developmental defects lead to partial or complete hormone deficiency and 3 significant health problems. The majority of cases are sporadic and of unknown cause. We 4 screened 28 patients with pituitary stalk interruption syndrome (PSIS) for mutations in the 5 FAT/DCHS family of protocadherins that have high functional redundancy. We identified 6 seven variants, four of which putatively damaging, in FAT2 and DCHS2 in six patients with 7 pituitary developmental defects recruited through a cohort of patients with mostly ectopic 8 posterior pituitary gland and/or pituitary stalk interruption. All patients had growth 9 hormone deficiency and two presented with multiple hormone deficiencies and small glands. FAT2 and DCHS2 were strongly expressed in the mesenchyme surrounding the 10 normal developing human pituitary. We analyzed Dchs2^{-/-} mouse mutants and identified 11 12 anterior pituitary hypoplasia and partially penetrant infundibular defects. Overlapping infundibular abnormalities and distinct anterior pituitary morphogenesis defects were 13 observed in Fat4^{-/-} and Dchs1^{-/-} mouse mutants but all animal models displayed normal 14 commitment to the anterior pituitary cell type. Together our data implicate FAT/DCHS 15 protocadherins in normal hypothalamic-pituitary development and identify FAT2 and DCHS2 16 17 as candidates underlying pituitary gland developmental defects such as ectopic pituitary gland and/or pituitary stalk interruption. 18

20 Introduction

Developmental pituitary defects affect 0.5 in 100,000 live births and may lead to varying degrees of pituitary hormone deficiency (1, 2). Beyond biochemical confirmation of hormonal defects, diagnosis is based on magnetic resonance imaging (MRI) to identify a small or absent anterior pituitary, interrupted or absent pituitary stalk (pituitary stalk interruption syndrome or PSIS) and ectopic posterior pituitary (EPP) (3).

26 During embryonic development, a region of the ventral diencephalon of the hypothalamus termed the infundibulum, and a region of the oral epithelium termed 27 28 Rathke's pouch (RP), evaginate towards each other to form the pituitary gland. These 29 actions are mediated by an array of developmental signals as well as the action of the surrounding mesenchyme (for review see (4)). RP gives rise to the anterior pituitary whilst 30 31 the infundibulum gives rise to the posterior pituitary and the pituitary stalk, which connects the posterior lobe to the hypothalamus. The vast majority of cases with pituitary 32 developmental defects are sporadic and of unknown cause; few cases appear to be familial 33 34 and they are often attributed to germline biallelic mutations in transcription factors 35 involved in the development of the infundibulum (5-7). Recently a whole exome sequencing (WES) screen of patients with such defects identified compound defects in DCHS1 among 36 37 other gene variants, indicating that protocadherins could be involved in pituitary development (8). 38

Cadherins represent a major family of adhesion molecules involved in tissue
formation. As such they possess extracellular domains which facilitate binding, as well as an
intracellular domain capable of associating with adaptor and signaling proteins (9). FAT and
DCHS protocadherins act as ligand-receptor pairs when expressed in adjacent cells and have

been implicated both in planar cell polarity (PCP) regulating cell movements such as
convergence-extension and cell migration (10, 11), as well as regulation of YAP/TAZ
independently of the Hippo kinase cascade (12-14), which controls tissue proliferation and
stem cell activity (15).

47 In humans there are four FAT paralogues (FAT1, FAT2, FAT3 and FAT4) and two DCHS paralogues (DCHS1 and DCHS2) (16). Mutations in FAT4 are linked to Hennekam syndrome, 48 whilst biallelic mutations in FAT4 or DCHS1 genes are associated with Van Maldergem 49 syndrome (VMS). Besides symptoms common to both syndromes, such as intellectual 50 51 disability and craniofacial malformations, VMS-specific clinical symptoms additionally 52 include camptodactyly, syndactyly, small kidneys, osteopenia and tracheal abnormalities (14, 17-21), whereas lymphangiectasia and lymphedema are specific to Hennekam 53 54 syndrome (17, 18, 22). A link between VMS and endocrine abnormalities including 55 hypogonadotropic hypogonadism and amazia, were reported in a recent study, providing 56 new support to the possible involvement of FAT/DCHS signaling in hypothalamic-pituitary 57 axis development or function (23). Null deletions of *Fat4* or *Dchs1* in mouse lead to 58 overlapping phenotypes, including inner ear, neural tube, kidney, skeleton, lung, and heart defects (24) further supporting that these protocadherins act as a ligand-receptor pair. 59 60 However, both mutant mice die shortly after birth, inhibiting the study of postnatal homozygous null animals (24, 25). *Dchs2^{-/-}* mutant mice are viable and fertile, with analyses 61 62 revealing functional redundancy between DCHS2 and DCHS1 (26). DCHS1 exhibits a broader 63 expression pattern during development and its loss generally results in more severe 64 developmental phenotypes (16). We have previously characterized expression patterns of 65 Dchs1, Fat3 and Fat4 during murine embryonic development and identified expression in the hypothalamus, infundibulum, developing RP and surrounding mesenchyme (27). 66

67	In this study we performed WES on 28 patients with EPP and/or PSIS and identified
68	variants in FAT2 and DCHS2 predicted to be deleterious. We characterized expression of
69	FAT2 and DCHS2 in the human developing gland and analyzed pituitary development in a
70	series of FAT/DCHS mouse mutants (Dchs1, Dchs2, Fat4), which identified a range of
71	infundibular and RP defects. Our data suggest a requirement for FAT and DCHS
72	protocadherins in the infundibulum and mesenchyme surrounding the developing gland
73	during morphogenesis, revealing that FAT/DCHS function is necessary for normal pituitary
74	morphogenesis and their dysfunction can underlie developmental anomalies of the
75	hypothalamic-pituitary axis.

Results

78 Molecular and *in silico* findings in patients with pituitary developmental defects

79	Combined with our description of expression of FAT/DCHS family members during pituitary
80	development (27), the recent identification of links between DCHS abnormalities and
81	pituitary developmental defects (8, 23) suggested an involvement of FAT/DCHS signaling in
82	hypothalamic and/or pituitary development. To address this possibility, we studied 28
83	patients with congenital pituitary abnormalities of EPP and/or PSIS to whole exome
84	sequencing, focusing on all four FAT genes, as well as DCHS1 and DCHS2. Three
85	heterozygous variants in DCHS2 and four in FAT2 were identified and their locations on the
86	proteins summarized in a schematic (Figure 1A). The variants, their functional type, class
87	(synonymous, non-synonymous, or frameshift), effect (missense, nonsense, silent),
88	frequency in control database and the genes in which these variants were identified in

patients with EPP are presented in Table 1. The allele frequency of all variants in the cohort
was 1.79%. Among all variants across these genes, only two variants in *DCHS2* and one
variant in *FAT2* were classified as functionally 'high' and predicted to be deleterious using
prediction tools (see Methods) (Table 1).

93 Clinical Data

94 The clinical and biochemical data of the six patients identified with FAT2 and DCHS2 variants 95 are summarized in Table 2. Patient D190 was a 20.6-year-old male at the time of assessment, who was born full-term with cryptorchidism and micropenis. He was diagnosed 96 97 with multiple anterior pituitary hormone deficiencies and learning difficulties and received 98 full hormone replacement therapy. MRI showed EPP and a very small anterior pituitary for 99 his age and sex (Figure 1B). The patient required testosterone treatment for micropenis and 100 for pubertal induction and maintenance. Despite long-term follow-up, he never presented any increment in testicular volume. He was found to harbor a DCHS2 stop codon c.C4027T 101 102 (p.R1343*) variant (Table 1). This was also found in the atherosclerosis risk in communities 103 study (ARIC) controls and is reported as a rare variant in the gnomAD database and likely 104 deleterious based on the CADD prediction tool (Table 1).

Patient D041 was a 16.4-year-old male who was born full term. He developed growth hormone deficiency (GHD) and was treated with recombinant growth hormone (rGH) until the age of 16 years. His pituitary MRI revealed EPP and an anterior pituitary within the normal size range for his age and sex (Figure 1B). Molecular analysis revealed a synonymous *FAT2* variation F1497= (Table 1). This is reported as a very rare variant in the gnomAD database, although it is predicted to be likely benign based on CADD score (Table 1).

Patient D965 was a 13.9-year-old male at the time of assessment who was born at 34 weeks 111 of gestation. He was diagnosed with GHD and MRI revealed an EPP (Table 2 and Figure 1B). 112 He was still under rGH treatment during clinical assessment. Molecular analysis revealed a 113 114 FAT2 c.C10426T variant which creates a stop codon at p.R3476*. This variant was not found in any of the controls, it is reported as a very rare variant in the gnomAD database and it is 115 likely deleterious according to the CADD prediction tool (Table 1). In addition, this patient was 116 117 also found to harbor a variant in DCHS2: c.836_837delAAinsG (p.K279Sfs*10), that creates a frameshift resulting in premature termination of translation. This variant was not found in 118 any of the controls and was absent from the gnomAD database (Table 1). 119

Patient D140 was a 20.7-year-old female who was born full-term. She was diagnosed with GHD following hypoglycemic seizures and received treatment with rGH (Table 2). Pituitary MRI revealed EPP and possible PSIS (Figure 1B, Table 2). She was found to harbor a *DCHS2* missense variant (p.T1328K) predicted to be damaging by all three prediction tools and has not been reported previously (Table 1).

125 Patient D831 was a 15.1-year-old male who was born pre-term at 31 weeks of gestation due 126 to premature rupture of membranes. He was diagnosed with GH, TSH and partial ACTH 127 deficiency as well as learning difficulties. He received rGH therapy until the age of 15 years 128 and is now on replacement with Levothyroxine and steroids (Table 2). Pituitary MRI revealed EPP and possible PSIS (Figure 1B, Table 2). Molecular analysis revealed a FAT2 p.R1250H 129 missense variant absent from public databases, predicted as probably damaging by Polyphen, 130 131 damaging by SIFT and likely deleterious by CADD. This was reported as very rare in the 132 gnomAD database (Table 1).

Patient D205 was a 14.6-year-old male at the time of assessment. He was born at term with
cryptorchidism and micropenis. He was diagnosed with GH and TSH deficiency and placed
under replacement with rGH and Levothyroxine (Table 2). He also required testosterone
treatment for micropenis and for pubertal induction and maintenance. MRI revealed EPP
(Figure 1). He was found to harbor a *FAT2* missense variant (p.D2720H), not reported
previously, and predicted to be probably damaging by Polyphen, damaging by SIFT and likely
deleterious by CADD (Table 1).

140

141 DCHS2 and FAT2 are expressed during embryonic pituitary development

To explore whether the two genes contribute to pituitary development, we next examined
expression of FAT2 and DCHS2 proteins in the developing human pituitary by
immunostaining. At 17 post-conception weeks (pcw), DCHS2 expression was detected in
mesenchymal cells around epithelial structures of the marginal zone as well as in diffuse
mesenchymal cells within the anterior lobe (arrows, Figure 2A). FAT2 expression was also
detected in mesenchymal cells, but also in the posterior lobe and at low levels in epithelial
structures within the marginal zone (Figure 2B).

Specific cross-reactivity of the FAT2 antibody allowed us to carry out analysis in the mouse pituitary. At 14.5dpc, FAT2 was abundantly detected in the mesenchyme surrounding the developing gland, in invading mesenchymal tissue that will form the vasculature (4, 28), as well as in cells at the external layer of the rostral RP (arrows) contacting the mesenchyme, and in the infundibulum (arrowheads) (Figure 2C). Expression of *Fat2* and *Dchs2* in the mesenchyme surrounding the developing RP and infundibulum was confirmed by mRNA in situ hybridization (Supplementary Figure 1). At 18.5dpc just prior to birth, FAT2 expression

remained strong in mesenchyme surrounding the pituitary; there was expression in the
posterior lobe and abundant signal detected throughout the vasculature of the anterior
lobe (Figure 2D). By 10-weeks in the adult mouse pituitary, FAT2 expression persisted in the
vasculature as confirmed by double immunofluorescence staining with Endomucin, marking
endothelial cells of the blood vessels (arrows, Figure 2E).

161

162 *Dchs2^{-/-}* mouse mutants have defects in hypothalamic-pituitary development

163 Considering the functional link suggested by the identification of PSIS patients with putatively pathogenic DCHS2 variants, we next sought to confirm such implication using a 164 Dchs2 mutant mouse model. In order to confirm if DCHS2 has a function during 165 hypothalamic-pituitary development, we analyzed Dchs2^{-/-} null mutants. Gross inspection of 166 167 the dissected mutant pituitary of neonates at P2 did not reveal any apparent morphological anomalies compared to controls (Supplementary Figure 2A, n=9). At 18.5dpc, a stage when 168 169 morphogenesis of the HP axis has been fully achieved, and when PSIS-like anatomical phenotypes can be unambiguously detected, embryos exhibited mild anterior pituitary 170 hypoplasia (3/6), accompanied by a significant reduction in the number of cycling cells as 171 172 determined by antibody staining against Ki-67 (average 26.3% cycling cells in controls 173 compared to 22.7% in mutants, P=0.0044 n=3, unpaired Student's t-test; Figure 3A). Analysis of cycling cells in the marginal zone surrounding the cleft and separately in the 174 parenchyme revealed a reduction in both regions of mutants compared to controls 175 176 (marginal zone *P*=0.0495, parenchyme *P*=0.007). We next sought to determine if anterior 177 cell type commitment and differentiation occurred normally. Immunofluorescence staining using antibodies against commitment markers PIT1 (POU1F1), SF1 (NR5A1), TPIT (TBX19) in 178

Dchs2^{-/-} and control Dchs2^{+/+} pituitaries did not reveal differences between genotypes
(Figure 3B), confirmed by qRT-PCR (Supplementary Figure 2B, n=4). Similarly, no differences
were observed for the expression of differentiation markers ACTH, GH and TSH (n=3, Figure
3B) or for the expression of the stem cell marker Sox2 (Supplementary Figure 2B). These
results are consistent with a role for DCHS2 in controlling morphogenesis rather than cell
fate specification within the AP.

Histological examination of frontal sections at 18.5dpc at anterior axial levels, revealed dysmorphology of the median eminence and developing pituitary stalk in a proportion of the mutants (4/6). Of note, the pituitary stalk in mouse is very short compared to the developing human pituitary. Mutant embryos exhibited invaginations in the median eminence and the epithelium of the infundibular recess (arrowheads Figure 3C, two mutant embryos shown, axial levels as indicated in the cartoon). None of these anomalies were observed in control littermates (n=8).

192

193 *Fat4^{-/-}* and *Dchs1^{-/-}* mutants exhibit additional morphogenetic defects of the anterior
 194 pituitary

The observation of variability in penetrance of the *Dchs2*^{-/-} null phenotypes suggested that there might be some functional redundancy compensating for the loss of *Dchs2*. Indeed, DCHS1 and DCHS2 act cooperatively during kidney development, acting with FAT4 as ligandreceptor pair (24, 26). This led us to explore the possibility that other members of the FAT/DCHS family might additionally contribute to pituitary development. We previously detected strong expression of *Fat4* in the rostral tip of the developing murine pituitary (which develops into the pars tuberalis), and strong expression of *Dchs1* in surrounding

mesenchyme (27). To characterize their expression during late pituitary development we 202 203 carried out RNAscope mRNA in situ hybridization using specific probes against Fat4 and Dchs1 in sagittal sections through wild type pituitaries at 18.5dpc. Fat4 expression was 204 205 strong in the developing pars tuberalis, the developing posterior lobe and pituitary stalk, and transcripts were also detected in the surrounding mesenchyme and scattered cells of 206 the developing anterior lobe. Low levels of *Dchs1* transcripts were detected throughout 207 208 these tissues with the highest expression in the pituitary stalk (Figure 4A). To investigate if Dchs1 expression increases in Dchs2^{-/-} mutants, indicative of a compensatory mechanism, 209 we carried out qRT-PCR on whole pituitary lysates comparing *Dchs2^{-/-}* and *Dchs2^{+/-}* control 210 genotypes. Although not significant with the available samples, there appears to be an 211 elevation of *Dchs1* mRNA levels in *Dchs2*^{-/-} mutants (Supplementary Figure 2B, n=4 per 212 genotype). 213

We hypothesized that loss of FAT4 or DCHS1 could also lead to pituitary defects. As 214 neither *Fat4^{-/-}* or *Dchs1^{-/-}* mutants are viable past the early postnatal period, analysis was 215 limited to embryonic stages and the perinatal period (P0-P2). As in Dcsh2^{-/-} mutants, 216 histological analysis of Fat4^{-/-} mutants at 13.0dpc revealed abnormal invaginations in the 217 218 epithelium of the infundibular recess in 7/10 embryos (arrowheads in Figure 4B). We also 219 observed a severely abnormal invagination of the infundibulum lacking a central lumen, using mRNA in situ hybridization against Fat3 to mark infundibular tissue (27) (1/10 220 embryos, Figure 4C). These infundibular anomalies were not observed in *Dchs1^{-/-}* embryos 221 (0/5 at 13.0dpc). The infundibular phenotypes shared between $Fat4^{-/-}$ and $Dchs2^{-/-}$ mutants 222 223 suggest that FAT4 may be acting in concert with DCHS2, as receptor-ligand pair, during posterior pituitary development. 224

225	Upon gross examination at P0, both <i>Fat4^{-/-}</i> and <i>Dchs1^{-/-}</i> pituitaries exhibited
226	shortening of the medio-lateral axis of the anterior pituitary compared to wild type
227	littermates (Figure 4C), unlike <i>Dchs2^{-/-}</i> mutants which did not display this phenotype (n=9,
228	Supplementary Figure 2A). The size of the intermediate and posterior lobes was comparable
229	to wild type controls (n=8 for <i>Fat4^{-/-}</i> , n=10 for <i>Dchs1^{-/-}</i>). Analysis of proliferation by Ki-67
230	immunostaining did not reveal differences in the number of cycling cells between genotypes
231	(Supplementary Figure 3, n=3 per genotype). Immunofluorescence staining of lineage
232	commitment and differentiation markers of the anterior pituitary (PIT1, SF1, TPIT, GH, TSH,
233	ACTH) identified normal distribution of committed and differentiated cell types in Fat4 ^{-/-}
234	pituitaries compared to controls (n=3, Figure 4D). No differences were observed between
235	Fat4 ^{-/-} and Dchs1 ^{-/-} genotypes (not shown).

236

237 **Discussion**

238 Screening 28 patients with EPP and/or PSIS, we have identified seven variants in FAT2 and 239 DCHS2 in six patients. Five of these variants were predicted to be damaging by in silico analysis. Indeed, the existence of familial cases with mutations and/or single nucleotide 240 241 variants in genes involved in the developmental process such as in HESX1, LHX4, PROP1, 242 OTX2, SOX3, PROKR2 and GPR161 have suggested a Mendelian form of inheritance (6, 7, 243 29). Recently, Zwaveling-Soonawala et al, also identified DCHS1 as one of the candidate 244 genes for sporadic PSIS in two young patients: a nine year old female who presented with absent stalk and anterior pituitary, EPP and hormonal deficiencies and a 2.5 year old male 245 with small stalk and anterior pituitary, EPP and hormonal deficiencies (8). Although no 246 functional studies were performed, both these patients had variants in other genes that 247

were also predicted to be damaging, such as in *GLI2* which has been reported to be involved
in holoprosencephaly and abnormal pituitary development (30) and in *BMP4*, which has a
crucial role during embryonic pituitary development (31) indicating that variants in one or
more genes other than *FAT2* and *DCHS2* may be required for an apparent phenotype.
In our screen, all patients with *FAT2* or *DCHS2* variants had GHD and three of them had
combined hormone deficiency. Two of these patients had a more severe phenotype with

254 complete deficiency of the adenohypophysis and a pituitary height smaller than expected255 for their age and sex.

Considering that in all *Dchs* and *Fat* mouse mutants analyzed, anterior cell type commitment and differentiation occurred normally, the hormonal deficiencies identified in our patients could be due to the lack of trophic signals of the hypothalamic releasing factors rather than defects in the differentiation of the anterior endocrine cells. In the patients, we were not able to identify a specific phenotype-genotype correlation, which indicates that these variants can be confounding factors, or causative where other factors also contribute to the severity of symptoms.

263 Expression analysis of both mouse and human tissue revealed that in development, 264 FAT/DCHS protocadherins are expressed in the mesenchyme surrounding the pituitary. The 265 infundibulum and posterior pituitary gland receive a rich blood supply from the superior 266 hypophyseal artery, infundibular artery and inferior hypophyseal artery (32), all of 267 mesenchymal origin (28, 33). Disruption of the pituitary vascular network can result in abnormal tissue morphology and poor function (28, 33). We postulate that mutations in 268 269 FAT2 and DCHS2 may affect the development of the posterior lobe and its connection to the 270 hypothalamus, through affecting the surrounding mesenchymal contribution. By analyzing

developing *Dchs2^{-/-}* mouse mutant pituitaries, we have identified a partially penetrant 271 pituitary stalk defect as well as anterior pituitary hypoplasia. Like Fat2-/- mice however, 272 these have previously been described as normal, healthy and viable, possibly due to the 273 274 redundant roles with other FAT and DCHS family members (26, 34). Consistent with this stalk phenotype, we also identified abnormal infundibular development in Fat4^{-/-} mutants, 275 previously shown to exhibit poor cerebral neuronal migration (14, 35). As such, the ventral 276 277 migration of axons of hypothalamic neurons located in the paired supraoptic and 278 paraventricular nuclei, which terminate in the posterior pituitary (4), might also be affected 279 by loss of FAT/DCHS protocadherins, resulting in abnormal evagination of this tissue and PSIS. 280

Interestingly, analysis of *Fat4^{-/-}* as well as *Dchs1^{-/-}* single mutants revealed an 281 additional pituitary defect, shortening of the medio-lateral axis of the anterior lobe. As this 282 283 is consistent between the two genotypes, we conclude that FAT4 and DCHS1, expressed in the developing RP, infundibulum and surrounding mesenchyme (27), are likely acting as 284 receptor-ligand pair in the morphogenesis of the anterior lobe, and we hypothesize that 285 expression of both proteins in the surrounding mesenchyme is critical for this process (27). 286 287 FAT4/DCHS1 may be involved in cell movements during development, which is consistent with their known role in planar cell polarity (10, 11, 25), often an important pathway during 288 289 dynamic rearrangement and migration of cells. In the anterior pituitary they are unlikely to 290 act upstream of YAP for this purpose, as previous work deregulating YAP levels during development did not result in medio-lateral morphogenesis defects (36). 291

Taken together, our studies have revealed a requirement for the concerted action of FAT/DCHS protocadherins for normal pituitary development and support the pathogenicity

of FAT2 and DCHS2 variants in patients with ectopic PSIS in addition to other genes reported 294 (8). As PSIS may present with isolated or multiple hormonal deficiencies, then neonatal 295 296 hypoglycemia, micropenis and/or cryptorchidism with or without growth deficit should 297 prompt early screening with hormonal and imaging investigations for early detection and treatment. Furthermore, genetic screening for identification of a specific mutation in the 298 299 genes involved in PSIS development is a prerequisite for genetic counseling and appropriate 300 long-term follow-up, which is imperative as there is a strong possibility of development of 301 other hormonal insufficiencies.

302 Methods

303 Whole exome sequencing of patients with ectopic posterior pituitary

The data from 28 unrelated patients diagnosed with non-syndromic EPP were reviewed and DNA was extracted from peripheral blood mononuclear cells. Whole exome sequencing and variant calling were performed for *FAT1*, *FAT2*, *FAT3*, *FAT4*, *DCHS1* and *DCHS2*. DNA samples from 156 in-house parents of osteosarcoma patients and 8,554 from Atherosclerosis Risk in Communities Study (ARIC) database were used as controls.

309 Analysis of the identified variants

310 The variants that were identified in controls were filtered and analysis was focused on the variants with functional type "high" and "moderate". Allele frequencies identified in 311 patients with EPP were compared to allele frequency published on reference database The 312 313 Genome Aggregation Database (gnomAD) spans 125,748 exome sequences and 15,708 314 whole-genome sequences from unrelated individuals and publicly available online 315 (https://gnomad.broadinstitute.org). The possible functional impact of an amino acid substitution was predicted by three different in silico prediction tools: (1) the PolyPhen 316 (Polymorphism Phenotyping) program (http://genetics.bwh.harvard.edu/pph2) which 317 318 calculates the position-specific independent counts (PSIC) score that represents the probability that a substitution be damaging; values nearer to 1 are more confidently 319 320 predicted to be deleterious, (2) for missense variants, the Sorting Intolerant From Tolerant 321 (SIFT) program [http://sift.jcvi.org] calculates normalized probabilities for all possible substitutions from the alignment. Positions with normalized probabilities less than 0.05 are 322 323 predicted to be deleterious; those greater than or equal to 0.05 are predicted tolerated. (3) 324 The Combined Annotation Dependent Depletion score (CADD, v1.3,

https://www.ncbi.nlm.nih.gov/pubmed/30371827) which combines deleteriousness
predictions from multiple algorithms into a single phred-like score for all possible single
nucleotide variants in the genome (i.e. a CADD score >10 is predicted to be amongst the top
10% most deleterious single nucleotide variants in the genome, CADD score >20 is amongst
the top 1%, CADD score >30 is amongst the top 0.1%, etc). For convenience we classified the
variants with a CADD score >20 as 'likely deleterious' and below 20 as 'likely benign'.

331 Animals

Dchs2^{-/-}, Fat4^{fi/fi} and Dchs1^{-/-} animals were previously described (24-26). For the generation
of Fat4^{-/-} animals, Fat4^{fi/fi} mice were crossed with the Actb^{Cre/+} strain for ubiquitous deletion
(37) and offspring were intercrossed. For embryo collection, the morning of vaginal plug was
considered 0.5dpc. Embryos or postnatal pituitaries were dissected, fixed in 10% NBF
overnight with agitation, then dehydrated through an ascending ethanol series. Tissues
were processed for paraffin embedding and sectioned to 4µm for RNAscope mRNA *in situ*hybridization, or 7µm for hematoxylin and eosin staining and immunofluorescence.

339 Hematoxylin and eosin staining

Slides were dewaxed in Histoclear (National Diagnostics) and rehydrated through a
descending ethanol series in dH₂O. Sections were stained with Harris' hematoxylin and
eosin following standard protocols. Slides were dehydrated and dried, then coverslips
mounted with VectaMount (Vector Ltd).

344 **RNAscope mRNA** *in situ* hybridization

Sections were processed and stained as described previously (27). Briefly, slides were
heated to 60°C, dewaxed in xylene and washed in 100% ethanol and processed following
the RNAscope 2.5HD Reagent Kit-RED assay kit (Advanced Cell Diagnostics) with specific
probes (*Fat4*, *Dchs1*, *Fat3*). Following detection, slides were weakly counterstained with
hematoxylin and coverslips mounted with VectaMount (Vector Ltd).

350 Immunofluorescence (IMF)

351 Slides were deparaffinized in Histoclear, rehydrated through a descending ethanol series, 352 followed by antigen retrieval in pH6.0 citrate buffer in a NXGEN Decloaking Chamber (Menari Diagnostics) at 110°C for 3min. Slides were washed in PBST (PBS with 0.1% Triton-353 X), blocked in Blocking Buffer (0.15% glycine, 2mg/ml BSA, 0.1% Triton-X in PBS) with 10% 354 355 sheep serum for 1h at room temperature, then incubated overnight in primary antibody in 356 Blocking Buffer with 1% sheep serum at 4°C. Primary antibodies used were against: DCHS2 (1:500, Atlas HPA064159), FAT2 (1:1000, Santa Cruz sc59985), Ki-67 (1:300, Abcam 357 ab16667), SOX2 (1:300, Abcam ab97959), PIT1 (1:1000, gift from Prof. S. Rhodes, University 358 of North Florida, USA), TPIT (1:300, gift from Prof. J. Drouin, University of Montreal, 359 Canada), SF1 (1:300, Life Technologies N1665), ACTH (1:300, Fitzgerald 10C-CR1096M1), GH 360 361 (1:1000, NHPP AFP5641801), TSH (1:1000 NHPP AFP-1274789). The Vector ImmPRESS kit was used for antibodies against SF1 according to the manufacturer's instructions. The 362 PerkinElmer TSA kit was used for antibodies against DCHS2 and FAT2, as previously 363 364 described (36). After primary antibody incubation, slides were washed in PBST then incubated with appropriate secondary antibodies (biotinylated goat anti-rabbit (1:300, 365 Abcam ab6720), biotinylated goat anti-mouse (1:300 Abcam ab6788)), and incubated with 366 367 fluorophore-conjugated Streptavidin (1:500, Life Technologies S11223) for 1h at room

temperature. Quenching of endogenous autofluorescence was carried out by treatment
with Sudan Black B following immunofluorescence against TPIT and SF1. Nuclei were
counterstained with Hoechst (1:10000, Life Technologies H3570). Coverslips were mounted
with VectaMount (Vector Laboratories, H1000).

372 Imaging

373 Wholemount images were taken with a MZ10 F Stereomicroscope (Leica Microsystems),

using a DFC3000 G camera (Leica Microsystems). For bright field images, stained slides were

375 scanned with Nanozoomer-XR Digital slide scanner (Hamamatsu) and images processed

- using Nanozoomer Digital Pathology View. Immunofluorescent staining was imaged with a
- 377 TCS SP5 confocal microscope (Leica Microsystems) and images processed using Fiji (38).

378 **Proliferation analysis**

The number of Ki-67 positive cells and total nuclei stained with Hoechst, were counted manually using Fiji (at least 5000 nuclei counted over 5-7 sections per biological sample) for control and mutant pituitaries, n=3 per genotype. Nuclei along the marginal zone epithelium were recorded separately to those within the anterior pituitary parenchyme.

383 Quantitative RT-PCR

Whole pituitaries were dissected from 10 week old *Dchs2^{+/-}* (control) and *Dchs2^{-/-}* (mutant) mice and placed in RNAlater-ice (Thermo Fisher, AM7030). They were flash frozen in liquid nitrogen and stored at -80°C. mRNA was extracted using Monarch Total RNA Miniprep kit (New England Biolabs, T2010S), translated using QuantiTect Reverse Transcription kit (Qiagen, 205311) then qRT-PCR was performed using QuantiNova SYBR Green RT-PCR kit (Qiagen, 208152) on a Roche Lightcycler 480. Data were analyzed using delta delta CT

- 390 method normalized to housekeeping gene expression, n=4 pituitaries per genotype. Primers
- 391 used: *Poulf1* (*Pit1*) fw CACGGCTCAGAATTCAGTCA, rv TCCAGAGCATCCTTAGCAGC; *Tbx19*
- 392 (Tpit) fw TGTCTCGCCTGCTTAACGTG, rv GACAGGGAACATCCGTCTGC; Nr5a1 (Sf1) fw
- 393 AGCTGCAAGGGCTTCTTCAA, rv CATTCGATCAGCACGCACAG; Sox2 fw
- 394 GAGGGCTGGACTGCGAACT, rv TTTGCACCCCTCCCAATTC; Dchs1 fw
- 395 TCCACGTTCATCCACTCAGC, rv GGGGACTGTTCTCACGAAGG; Hprt (housekeeping) fw
- 396 GTTGGGCTTACCTCACTGCT, rv TCATCGCTAATCACGACGCT; Actb (housekeeping) fw
- 397 TTCTTTGCAGCTCCTTCGTT, rv ATGGAGGGGAATACAGCCC.

398 Statistics

- 399 Data were analyzed using two-tailed unpaired Student's t-tests using the Holm-Sidak
- 400 method to correct for multiple analysis, where P<0.05 was taken to be statistically

401 significant.

402 Study Approval

- 403 All participants, or their legal guardian, provided written and informed consent. The present
- 404 studies in humans were reviewed and approved by the Irmandade da Santa Casa de
- 405 Misericórdia de São Paulo review board (project number 34003914.0.0000.5479), located at
- 406 Marquês de Itu Street, 381, São Paulo, Brazil. Animal husbandry was carried out under
- 407 compliance of the Animals (Scientific Procedures) Act 1986, relevant Home Office License
- 408 (P5F0A1579) and KCL Ethical Review approval.

409

410 AUTHOR CONTRIBUTIONS

Designing research studies: FH, CAS, CLA; conducting experiments: EJL, PX, AS, TSS, FRF, DS,
ALP; acquiring data: EJL, PX, TSS, CK, CAL, AS, JLM, NP, JL, CLA; analyzing data: EJL, PX, AS, FRF;
providing reagents: TH, PF-W, FH, CAS; writing the manuscript: PX, EJL, CLA; editing the
manuscript: PF-W, FH, JLM, CAS.

415

416 **ACKNOWLEDGEMENTS**

We thank the patients and their families for participating in the described studies. This study 417 418 was supported by grants MR/L016729/1 from the MRC (CLA), a Lister Institute Research Prize Fellowship to CLA, RG130699 from The Royal Society (CLA), the Deutsche 419 420 Forschungsgemeinschaft (DFG) within the 314061271 - TRR 205 (CLA), the AFM-Téléthon (Association Française contre les myopathies) grant 20861 (FH), grant BB/M022544/1 from 421 the BBSRC (PF-W). This study was in part funded by the intramural research program of the 422 423 Eunice Kennedy Shriver National Institute of Child Health of Human Development (NICHD), 424 Bethesda, MD20892, USA. We are grateful to Prof. Jacques Drouin and Prof. Simon Rhodes for TPIT and PIT antibodies respectively, and the National Hormone and Peptide Program 425 426 (Harbor-University of California, Los Angeles Medical Center) for providing some of the hormone antibodies used in this study. We thank Prof. Kenneth Irvine for continued advice 427 428 and sharing reagents and Prof. Helen McNeill for providing the *Fat4* mouse mutant.

429

430 **References**


Bar C, et al. Pituitary Stalk Interruption Syndrome from Infancy to Adulthood: Clinical,
 Hormonal, and Radiological Assessment According to the Initial Presentation. *PloS one.* 2015;10(11):e0142354.

- Voutetakis A, Sertedaki A, Dacou-Voutetakis C. Pituitary stalk interruption syndrome:
 cause, clinical manifestations, diagnosis, and management. *Current opinion in pediatrics.* 2016;28(4):545-550.
- 437 3. Fujisawa I, et al. Transection of the pituitary stalk: development of an ectopic posterior
 438 lobe assessed with MR imaging. *Radiology*. 1987;165(2):487-489.
- 439 4. Cheung LY, Davis SW, Brinkmeier ML, Camper SA, Perez-Millan MI. Regulation of 440 pituitary stem cells by epithelial to mesenchymal transition events and signaling 441 pathways. *Mol Cell Endocrinol.* 2017;445:14-26.
- Tatsi C, et al. Pituitary stalk interruption syndrome and isolated pituitary hypoplasia may
 be caused by mutations in holoprosencephaly-related genes. *J Clin Endocrinol Metab.*2013;98(4):E779-784.
- 6. Reynaud R, et al. PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. *J Clin Endocrinol Metab.* 2012;97(6):E1068-1073.
- Reynaud R, et al. Pituitary stalk interruption syndrome in 83 patients: novel HESX1
 mutation and severe hormonal prognosis in malformative forms. *European journal of endocrinology*. 2011;164(4):457-465.
- Zwaveling-Soonawala N, et al. Clues for Polygenic Inheritance of Pituitary Stalk
 Interruption Syndrome From Exome Sequencing in 20 Patients. *J Clin Endocrinol Metab.* 2018;103(2):415-428.
- 453 9. Tanoue T, Takeichi M. New insights into Fat cadherins. *Journal of cell science*.
 454 2005;118(Pt 11):2347-2353.
- 455 10. Mao Y, et al. Dchs1-Fat4 regulation of polarized cell behaviours during skeletal 456 morphogenesis. *Nature communications.* 2016;7:11469.
- 457 11. Zakaria S, et al. Regulation of neuronal migration by Dchs1-Fat4 planar cell polarity.
 458 *Current biology : CB.* 2014;24(14):1620-1627.
- Ragni CV, et al. Amotl1 mediates sequestration of the Hippo effector Yap1 downstream
 of Fat4 to restrict heart growth. *Nature communications.* 2017;8:14582.
- 461 13. Crespo-Enriquez I, et al. Dchs1-Fat4 regulation of osteogenic differentiation in mouse.
 462 Development (Cambridge, England). 2019;146(14).
- 463 14. Cappello S, et al. Mutations in genes encoding the cadherin receptor-ligand pair DCHS1
 464 and FAT4 disrupt cerebral cortical development. *Nature genetics.* 2013;45(11):1300465 1308.
- 466 15. Blair S, McNeill H. Big roles for Fat cadherins. *Current opinion in cell biology*. 2018;51:73467 80.
- Rock R, Schrauth S, Gessler M. Expression of mouse dchs1, fjx1, and fat-j suggests
 conservation of the planar cell polarity pathway identified in Drosophila. *Developmental*

- 470 dynamics : an official publication of the American Association of Anatomists.
 471 2005;234(3):747-755.
- 472 17. Ivanovski I, et al. Van Maldergem syndrome and Hennekam syndrome: Further
 473 delineation of allelic phenotypes. *American journal of medical genetics Part A*.
 474 2018;176(5):1166-1174.
- 475 18. Alders M, et al. Hennekam syndrome can be caused by FAT4 mutations and be allelic to
 476 Van Maldergem syndrome. *Human genetics.* 2014.
- 477 19. Mansour S, et al. Van Maldergem syndrome: further characterisation and evidence for
 478 neuronal migration abnormalities and autosomal recessive inheritance. *European*479 *journal of human genetics : EJHG.* 2012;20(10):1024-1031.
- Zampino G, et al. Cerebro-facio-articular syndrome of Van Maldergem: confirmation of
 a new MR/MCA syndrome. *Clinical genetics.* 1994;45(3):140-144.
- 482 21. van Maldergem L, Wetzburger C, Verloes A, Fourneau C, Gillerot Y. Mental retardation
 483 with blepharo-naso-facial abnormalities and hand malformations: a new syndrome?
 484 *Clinical genetics.* 1992;41(1):22-24.
- 485 22. Hennekam RC, et al. Autosomal recessive intestinal lymphangiectasia and lymphedema,
 486 with facial anomalies and mental retardation. *American journal of medical genetics*.
 487 1989;34(4):593-600.
- Sotos J, et al. A patient with van Maldergem syndrome with endocrine abnormalities,
 hypogonadotropic hypogonadism, and breast aplasia/hypoplasia. *International journal*of pediatric endocrinology. 2017;2017:12.
- 491 24. Mao Y, et al. Characterization of a Dchs1 mutant mouse reveals requirements for Dchs1492 Fat4 signaling during mammalian development. *Development (Cambridge, England)*.
 493 2011;138(5):947-957.
- 494 25. Saburi S, et al. Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to
 495 cystic kidney disease. *Nature genetics.* 2008;40(8):1010-1015.
- 496 26. Bagherie-Lachidan M, et al. Stromal Fat4 acts non-autonomously with Dachsous1/2 to
 497 restrict the nephron progenitor pool. *Development (Cambridge, England).* 2015.
- 498 27. Lodge EJ, Russell JP, Patist AL, Francis-West P, Andoniadou CL. Expression Analysis of
 499 the Hippo Cascade Indicates a Role in Pituitary Stem Cell Development. *Frontiers in*500 *physiology*. 2016;7:114.
- 50128.Davis SW, et al. beta-catenin is required in the neural crest and mesencephalon for502pituitary gland organogenesis. BMC developmental biology. 2016;16(1):16.
- 50329.Fang Q, et al. Genetics of Combined Pituitary Hormone Deficiency: Roadmap into the504Genome Era. Endocrine reviews. 2016;37(6):636-675.

- 50530.Arnhold IJ, Franca MM, Carvalho LR, Mendonca BB, Jorge AA. Role of GLI2 in506hypopituitarism phenotype. J Mol Endocrinol. 2015;54(3):R141-150.
- 507 31. Ericson J, Norlin S, Jessell TM, Edlund T. Integrated FGF and BMP signaling controls the
 508 progression of progenitor cell differentiation and the emergence of pattern in the
 509 embryonic anterior pituitary. *Development (Cambridge, England)*. 1998;125(6):1005 510 1015.
- 511 32. Ciofi P, et al. Brain-endocrine interactions: a microvascular route in the mediobasal 512 hypothalamus. *Endocrinology*. 2009;150(12):5509-5519.
- Scully KM, et al. Epithelial cell integrin β1 is required for developmental angiogenesis in
 the pituitary gland. *Proceedings of the National Academy of Sciences.*2016;113(47):13408-13413.
- 51634.Barlow JL, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse517model of human 5q- syndrome. Nature medicine. 2010;16(1):59-66.
- 35. Zakaria S, et al. Regulation of neuronal migration by dchs1-fat4 planar cell polarity.
 Current biology : CB. 2014;24(14):1620-1627.
- 520 36. Lodge EJ, et al. Homeostatic and tumourigenic activity of SOX2+ pituitary stem cells is 521 controlled by the LATS/YAP/TAZ cascade. *eLife*. 2019;8.
- 522 37. Lewandoski M, Meyers EN, Martin GR. Analysis of Fgf8 gene function in vertebrate 523 development. *Cold Spring Harb Symp Quant Biol.* 1997;62:159-168.
- 524 38. Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. *Nature* 525 *methods.* 2012;9(7):676-682.

527	Figure 1. Variants in FAT2 and DCHS2 in patients with PSIS. (A) Representative schematic of
528	the FAT2 and DCHS2 proteins indicating the locations of identified mutations. Variants in
529	red are predicted likely deleterious by CADD score (>20). No CADD score data available for
530	DCHS2 p.K279Sfs*10. (B) Sagittal T1 pituitary MRIs of the six patients with FAT2/DCHS2
531	variants and normal MRI for comparison, bottom left. For each patient, the normal posterior
532	pituitary bright spot is not seen in the pituitary fossa, rather, an ectopic small region of high
533	T1 signal at the top of the infundibulum or higher (red arrows). PS: pituitary stalk, AP:
534	anterior pituitary, PP: posterior pituitary (normal intrasellar).
535	
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	




547 Figure 2. DCHS2 and FAT2 expression in the developing pituitary. (A,B)

548 Immunofluorescence staining on 17 post-conception week (pcw) human fetal pituitary sections, using specific antibodies against DCHS2 (A) and FAT2 (B), n=2. DCHS2 is expressed 549 550 in mesenchymal tissues surrounding epithelial structures in the marginal zone, between the posterior and anterior pituitary and within the anterior lobe (arrows). FAT2 localizes in 551 mesenchymal tissues within the anterior lobe, is expressed throughout the posterior lobe 552 553 and diffuse staining is observed in epithelial structures in the marginal zone. Images in (i) 554 and (ii) are magnified boxed regions in (A) and (B). (C,D) Immunofluorescence staining using 555 antibodies against FAT2 on the developing mouse pituitary at 14.5 days post coitum (dpc) (C) and 18.5dpc (D), n=3. At 14.5dpc FAT2 localizes in mesenchymal tissue Rathke's pouch 556 (RP), in cells of (RP) making contact with the mesenchyme (arrows) and in cells of the 557 558 infundibulum (arrowheads) (C). At 18.5dpc, FAT2 expression persists in the mesenchyme 559 surrounding the gland, throughout the posterior lobe and in vasculature throughout the anterior lobe (D). (E) In the wild type adult pituitary at 10 weeks, FAT2 (green) is expressed 560 561 strongly by cells of the vasculature, as seen by double-immunofluorescence staining with Endomucin (red) marking endothelial cells (E), n=3. PL: posterior lobe, AL: anterior lobe, IL: 562 intermediate lobe, MZ: marginal zone, Inf: infundibulum, RP: Rathke's pouch, M: 563 mesenchyme, Sph: sphenoid bone, BV: blood vessels. Scale bars: 200µm in (A-C), 100µm in 564 (E). 565

566

567




570 Figure 3. DCHS2 is required for normal murine pituitary development. (A)


571 Immunofluorescence staining using antibodies against Ki-67 to detect cycling cells, on frontal sections of pituitaries from *Dchs2^{-/-}* mutants and wild type littermate controls at 572 573 18.5dpc. Graph depicting quantification of cycling cells of the anterior pituitary of wild type controls and *Dchs2^{-/-}* mutants, showing reduced proliferation in mutants in the marginal 574 zone (MZ) surrounding the cleft P=0.0495, parenchyme (Par) P=0.007 and total throughout 575 576 the anterior lobe P=0.0044, unpaired Student's t-test (n=3 per genotype, multiple sections 577 counted). Values of Ki-67 positive cells are expressed as a percentage of the total nuclei in 578 the anterior lobe. Average values are indicated. (B) Immunofluorescence staining on Dchs2-/pituitaries and littermate controls at 18.5dpc (n=3) using antibodies against lineage-579 committed progenitor markers PIT1 (thyrotrophs, somatotrophs, lactotrophs), SF1 580 (gonadotrophs) and TPIT (corticotrophs, melanotrophs) and hormones TSH, GH and ACTH 581 582 expressed in differentiated thyrotrophs, somatotrophs and corticotrophs, respectively. Staining is comparable for all markers between genotypes. (C) Hematoxylin and eosin 583 staining on frontal sections of *Dchs2^{-/-}* mutants and control at 18.5dpc at axial levels as 584 indicated in the cartoon (n=6). Abnormal invaginations are seen in the median eminence 585 (arrowheads) as wells as lobulated protrusions (arrow). PL: posterior lobe, IL: intermediate 586 lobe, AL: anterior lobe, Hyp: hypothalamus, M: mesenchyme, Sph: sphenoid bone. Scale 587 bars: 200µm in (A) and (B), 250µm in (C). 588

589

590



593	Figure 4. FAT4 and DCHS1 are required for normal murine pituitary development. (A)
594	RNAscope mRNA in situ hybridization on sagittal sections through wild type murine
595	pituitaries at 18.5dpc using probes against <i>Fat4</i> and <i>Dchs1</i> (n=3). Abundant <i>Fat4</i> transcripts
596	are detected in the pars tuberalis, the infundibulum, developing pituitary stalk and
597	mesenchyme surrounding definitive Rathke's pouch. Some transcripts are also detected in
598	RP. Expression of <i>Dchs1</i> is detected at low levels throughout these tissues. (B) Hematoxylin
599	and eosin staining of sagittal sections through <i>Dchs1^{-/-}</i> (n=5), <i>Fat4^{-/-}</i> (n=10) and control
600	pituitaries (n=15) at 13.0dpc showing invaginations in the infundibulum of <i>Fat4^{-/-}</i> mutants
601	(arrowheads), not observed in control or <i>Dchs1^{-/-}</i> embryos. RNAscope mRNA <i>in situ</i>
602	hybridization on sagittal sections through control wild type and <i>Fat4^{-/-}</i> pituitaries at 13.5dpc
603	using specific probes against <i>Fat3</i> marking the ventral diencephalon and infundibulum,
604	which is abnormal in mutants (arrowheads). (C) Wholemount images taken at dorsal (top
605	panels) and frontal views (bottom panel) of control, <i>Dchs1^{-/-}</i> (n=10) and <i>Fat4^{-/-}</i> (n=8)
606	pituitaries at PO. Both <i>Dchs1^{-/-}</i> and <i>Fat4^{-/-}</i> mutants have a shortened medio-lateral axis
607	affecting the anterior lobe compared to control. (D) Immunofluorescence staining on <i>Fat4</i> -/-
608	pituitaries and littermate controls at 18.5dpc using antibodies against lineage-committed
609	progenitor markers PIT1, TPIT and SF1 and hormones TSH, GH and ACTH (n=3). Staining is
610	comparable for all markers between genotypes. Inf: infundibulum, PS: pituitary stalk, PT:
611	pars tuberalis, RP: Rathke's pouch, M: mesenchyme, VD: ventral diencephalon, PL: posterior
612	lobe, IL: intermediate lobe, AL: anterior lobe. Scale bars: 250 μ m in (A) and (B), 100 μ m in (D).



TABLES

Table 1. Mutations/variations of FAT/DCHS identified in patients with EPP

Patient Code	Gene	Functional Type	Func. refGene	SNP Effect	Functional Class	Codon Change	Amino Acid Change	Frequency in the Genome Aggregation Database	CADD score
D190	DCHS2	HIGH	exonic	NONSENSE	STOP GAINED	Cga/Tga	p.Arg1343Ter	0.135% rs150179829	38
D041	FAT2	LOW	exonic	SILENT	SYNONYMOUS	ttC/ttT	p.Phe1497=	0.00119% rs1024234841	11.57
D965	DCHS2	HIGH	exonic	NONSENSE	FRAMESHIFT	aaa/aG-	p.Lys279Serfs*10	0.00%	Not available
D965	FAT2	HIGH	exonic	NONSENSE	STOP GAINED	Cga/Tga	p.Arg3476Ter	0.000398% rs377026428	55
D140	DCHS2	MODERATE	exonic	MISSENSE	NONSYNONYMOUS CODING	aCa/aAa	p.Thr1328Lys	0.00%	27.5
D831	FAT2	MODERATE	exonic	MISSENSE	NONSYNONYMOUS CODING	cGc/cAc	p.Arg1250His	0.00168% rs145224294	34
D205	FAT2	MODERATE	exonic	MISSENSE	NONSYNONYMOUS CODING	Gat/Cat	p.Asp2720His	0.00%	23.4

Patient code	Sex	Age at the time of study (yrs)	Weight at the time of study (kg)	Height at the time of study (cm)	Endocrine disorders	Other findings	Pituitary height (mm)	Normal mean pituitary height (mm ±SD) for age ¹
D190	Male	20.6	N/A	N/A	GHD, TSHD, ACTHD,	micropenis, cryptorchidism	2	5.63 ±1.00
D041	Male	16.4	59.7	162.9	GHD	NR	4	5.10 ±1.17
D965	Male	13.9	55	165	GHD	NR	4	5.10 ±1.17
D140	Female	20.7	45.2	155	GHD	NR	4	6.48 ± 0.95
D831	Male	15.1	46	159.8	GHD, TSHD, partial ACTHD	NR	3	5.10 ±1.17
D205	Male	14.6	54.7	161.8	GHD, TSHD	micropenis, cryptorchidism	4	5.10 ±1.17

Table 2. Clinical data and pituitary height of patients with variants in FAT2 and/or DCHS2

¹Tsunoda et al, Am J Neuroradiol 1997; 18:551–554

GHD: Growth hormone deficiency, TSHD: Thyrotropin hormone deficiency, ACTHD: Adrenocorticotropin hormone deficiency, NR: none reported, N/A: not available.